Skip to main content

MorphoSys, Astellas Extend Antibody Library License

NEW YORK (GenomeWeb News) – The German antibody developer Morphosys has extended an agreement with Astellas Pharma that allows the Japanese pharmaceutical company to use the HuCAL Gold antibody library for therapeutics development for four more years.
 
The companies extended an agreement they signed in March 2007 that gives Astellas access to the antibody library at its Tsukuba, Japan, facility through 2012, and they renewed an option for commercialization and development of therapeutic antibodies.
 
Under the agreement, MorphySys will receive annual user fees for the HuCAL platform and may receive exclusive license fees, milestones, and royalty payments from any therapeutics Astellas markets that were derived from MorphySys’ technology.
 

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.